Vancouver, Canada - August 1, 2025 - Evasc Neurovascular today announced the publication of groundbreaking real-world clinical data from its prospective, multi-center global registry evaluating the two eCLIPs generations delivery systems in over 280 patients. The results, published in Neurosurgery, confirm that the eCLIPs system delivers durable, efficient, and safe outcomes in the treatment of wide-neck bifurcation aneurysms (WNBAs). In parallel, Evasc announced CE/MDR approval and the limited commercial launch of the new 021 eCLIPs eBFD Flow Diverter - a device specifically engineered to treat bifurcation aneurysms at the middle cerebral artery (MCA) and anterior communicating artery (ACom).
The global registry evaluated both generations of the eCLIPs system-eBRS and eB-and demonstrated a 96% satisfactory occlusion rate (mRROC 1 + 2). Complete occlusion rates were 77% for eBRS and 81% for eB, significantly outperforming intra-saccular devices and conventional stent-assisted coiling in bifurcation aneurysms. "These results reinforce the long-term value of eCLIPs in achieving durable occlusion for wide-neck bifurcation aneurysms," said Dr. Tom Marotta, Interventional Neuroradiologist at St. Michael's Hospital, University of Toronto. "The eCLIPs is becoming an essential tool in our neurointerventional arsenal." The study also highlighted the evolution from the archived first-generation eCLIPs to the now widely adopted second generation eCLIPs system.
The current-generation eCLIPs features:
Evasc is proud to announce the limited release of its 021 eCLIPs Flow Diverter (eBFD), specifically designed for short landing zone anatomies, especially MCA and ACom bifurcations.
Key features of the 021 eBFD:
"The 021 compatible eCLIPs Flow Diverter represents the next evolution in our mission to address all anatomical challenges associated with WNBAs," said Sean Jager, VP of Engineering at Evasc Neurovascular. "With this device, we now offer a complete portfolio of flow-diverting, neck-bridging solutions for both 021 and 027 catheter platforms. Moreover, coupled with the coil-retaining eB version, eCLIPs technology can be applied to a broader range of WNBAs than any other single commercial product, including low-aspect ratios and neck lengths up to 12mm, regardless of dome-to-neck ratio." The company is also anticipating the results of the EESIS-France study, expected to deliver a robust, core lab-adjudicated dataset that will further validate the clinical value of eCLIPs.
Evasc Neurovascular, headquartered in Vancouver, Canada, is a global leader in the development of innovative medical devices for the treatment of cerebral aneurysms. With a focus on clinical excellence, cutting-edge engineering, and patient outcomes, Evasc is redefining the standard of care for wide-neck bifurcation aneurysms and other complex neurovascular conditions.
For more information, please visit www.evasc.com or contact:
Scott Wilson
Chief Financial Officer & Investor Relations
+1 (604) 742-3811
wilson@evasc.com
107-1099 West 8th Avenue
Vancouver, BC, Canada V6H 1C3
+1 (604) 742-3811